Side-by-side comparison of AI visibility scores, market position, and capabilities
Melbourne FL defense electronics (NYSE: LHX) $21.3B FY2024 revenue (+8%); tactical radios, ISR, electronic warfare, JADC2 networks, Falcon radio family competing with Raytheon and Northrop Grumman.
L3Harris Technologies, Inc. is a Melbourne, Florida-based defense electronics and technology company — publicly traded on the New York Stock Exchange (NYSE: LHX) as an S&P 500 Industrials component — providing advanced defense electronics, intelligence, surveillance and reconnaissance (ISR) systems, communication systems, and aviation products for US and allied defense forces through approximately 47,000 employees across four segments: Integrated Mission Systems (ISR aircraft modifications, electro-optical/infrared systems, maritime patrol aircraft), Space & Airborne Systems (military satellite communications, electronic warfare, precision weapons guidance), Communication Systems (tactical radio communications, night vision devices, public safety communications), and Aerojet Rocketdyne (integrated into L3Harris via investment, pending completion). L3Harris Technologies was formed in June 2019 through the merger of L3 Technologies and Harris Corporation — combining Harris's radio communication and space systems expertise with L3's ISR sensors, aircraft modification, and training systems capabilities to create the sixth-largest US defense contractor by revenue. In fiscal year 2024, L3Harris reported revenues of $21.3 billion (+8% year-over-year), with strong growth driven by JADC2 (Joint All-Domain Command and Control) radio and network programs, F-35 avionics subsystems production, and international NATO ally military communication equipment demand. CEO Christopher Kubasik has focused on margin improvement and portfolio optimization — divesting non-core businesses (commercial aviation training — sold Pilot Training business, Link Simulation & Training to CAE) while investing R&D in the electronic warfare (EW) and space domain awareness capabilities where L3Harris holds differentiated technology advantages.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.